PDF herunterladen
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0045-1809310
Case Report

Diagnostic Challenges in a Case of Suspected Breast Cancer with Low FDG Uptake and an Incidental Thyroid Lesion: A Case Report and Literature Review

Raydel Briankwee Amalo 
1   Department of Nuclear Medicine and Theranostic Molecular, School of Medicine, Universitas Padjajaran, Hasan Sadikin General Hospital, Bandung, Indonesia
,
Yustia Tuti
2   Department of Nuclear Medicine and Theranostic Molecular, Dharmais Cancer General Hospital, Jakarta, Indonesia
,
Ayu Rosemeilia Dewi
2   Department of Nuclear Medicine and Theranostic Molecular, Dharmais Cancer General Hospital, Jakarta, Indonesia
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction

The coexistence of multiple malignancies presents diagnostic and therapeutic challenges. Breast and thyroid cancers are among the most frequently diagnosed malignancies in women, and studies suggest a potential bidirectional association. While fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) is a valuable imaging modality for evaluating breast cancer, its sensitivity in detecting low-metabolic subtypes remains limited. Additionally, incidental FDG-avid thyroid lesions require further evaluation due to their potential malignancy risk.

Case Report

We present a 61-year-old female with a suspected left breast malignancy, suggestive of luminal A subtype, showing low FDG uptake (maximum standardized uptake value [SUVmax] 2.0) on PET/CT, despite mammographic and ultrasound findings suggestive of malignancy (Breast Imaging-Reporting and Data System 4A and V). Additionally, an incidental left thyroid lesion (4.0 × 3.8 cm, SUVmax 3.4) with calcifications was detected, raising suspicion for malignancy. The discordant imaging findings in this case highlight the limitations of FDG-PET/CT and emphasize the necessity of multimodal imaging and histopathological confirmation.

Conclusion

This case underscores the importance of integrating multiple imaging modalities for accurate diagnosis. While PET/CT is useful for systemic staging, its limitations in detecting certain breast cancer subtypes necessitate complementary imaging techniques and histopathological confirmation. The incidental thyroid lesion also required further assessment, reinforcing the need for a comprehensive diagnostic approach.

Keywords

bidirectional breast and thyroid cancer - breast cancer - dual malignancy - incidentaloma thyroid - low FDG Uptake


Publikationsverlauf

Artikel online veröffentlicht:
19. Mai 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Nielsen SM, White MG, Hong S. et al. The breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2016; 25 (02) 231-238
    PubMedSuche in Google Scholar
  • 2 Hindié E, Hindié E. The EANM-SNMMI guideline on the role of [18F]FDG-PET/CT in breast cancer: important milestones and perspectives for the future. Eur J Nucl Med Mol Imaging 2024; 51 (09) 2695-2700
    PubMedSuche in Google Scholar
  • 3 Carkaci S, Adrada BE, Rohren E. et al. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?. Acad Radiol 2012; 19 (05) 535-541
    PubMedSuche in Google Scholar
  • 4 Lee MI, Jung YJ, Kim DI. et al. Prognostic value of SUVmax in breast cancer and comparative analyses of molecular subtypes: a systematic review and meta-analysis. Medicine (Baltimore) 2021; 100 (31) e26745
    PubMedSuche in Google Scholar
  • 5 Gradishar WJ, Moran MS, Abraham J. et al. Breast cancer, version 3.2024. J Natl Compr Canc Netw 2024; 22 (05) 331-357
    PubMedSuche in Google Scholar
  • 6 Dunne RM, O'Mahony D, Wilson G, McDermott R, O'Keeffe SA. The role of the breast radiologist in evaluation of breast incidentalomas detected on 18-fludeoxyglucose positron emission tomography/CT. Br J Radiol 2013; 86 (1026) 20130034
    PubMedSuche in Google Scholar
  • 7 Dong A, Wang Y, Lu J, Zuo C. Spectrum of the breast lesions with increased 18F-FDG uptake on PET/CT. Clin Nucl Med 2016; 41 (07) 543-557
    PubMedSuche in Google Scholar
  • 8 Murakami R, Fukushima Y, Tani H. et al. Prognostic value of SUVmax of 18F-FDG PET/CT in early-stage breast cancer with no lymph node metastasis. Open J Med Imaging. 2017; 7 (03) 112-123
    Suche in Google Scholar
  • 9 Aktolun C, Goldsmith SJ. eds. Nuclear Oncology. 1st ed.. Philadelphia: Wolters Kluwer Health; 2014
    Suche in Google Scholar
  • 10 McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH. The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 2007; 142 (06) 837-844 , discussion 844.e1–844.e3
    PubMedSuche in Google Scholar
  • 11 Raza SN, Shah MD, Palme CE, Hall FT, Eski S, Freeman JL. Risk factors for well-differentiated thyroid carcinoma in patients with thyroid nodular disease. Otolaryngol Head Neck Surg 2008; 139 (01) 21-26
    PubMedSuche in Google Scholar
  • 12 Bae JS, Chae BJ, Park WC. et al. Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol 2009; 7: 63
    CrossrefPubMedSuche in Google Scholar
  • 13 Chun AR, Jo HM, Lee SH. et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Endocrinol Metab (Seoul) 2015; 30 (01) 71-77
    PubMedSuche in Google Scholar
  • 14 Stangierski A, Woliński K, Czepczyński R. et al. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET/CT examination. PLoS One 2014; 9 (10) e109612
    PubMedSuche in Google Scholar
  • 15 Bolf EL, Sprague BL, Carr FE. A linkage between thyroid and breast cancer: a common etiology?. Cancer Epidemiol Biomarkers Prev 2019; 28 (04) 643-649
    CrossrefPubMedSuche in Google Scholar
  • 16 Tan H, Wang S, Huang F, Tong Z. Association between breast cancer and thyroid cancer risk: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne) 2023; 14: 1138149
    PubMedSuche in Google Scholar
  • 17 Bakos B, Kiss A, Árvai K. et al. Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden. BMC Cancer 2021; 21 (01) 706
    PubMedSuche in Google Scholar